Call Me
0780 848 3333
0161 388 1961
0161 495 7000
0161 447 6600
0161 447 6700
Connect With Email
privatechestclinic@gmail.com ann.stephens@bmichoice.co.uk madelaine.fox@bmichoice.co.ukClinic Timing
BMI Alexandra Hospital
Tuesday: 6.30pm - 8pm
Spire Manchester Hospital
Friday: 8am - 12pm
What is research and why is it important to me? Research is about finding out new knowledge that could lead to changes in treatments, policies or care. In other words, research is my way of understanding the needs and help speedy recovery of my little patients. My focus of research has been on Asthma, epidemiology of common respiratory illnesses, Cystic Fibrosis, Primary ciliary dyskinesia and Non cystic fibrosis bronchiectasis. Here is a sample of some of the research that I have undertaken as a Principal Investigator.
CF START: The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF. Non-commercial. Ongoing. Non – commercial
ALPINE 2: AZLI for children with CF and PA lung infection – Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization (Gilead Pharmaceuticals). Opening soon. Commercial
VX15-770-126 ARRIVAL Extension Study: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment (Vertex Pharmaceuticals). Ongoing. Commercial
VX15-770-124 ARRIVAL Study: A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who are Less than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation (Vertex Pharmaceuticals). Completed. Commercial
Cystic Fibrosis: The impact of Cystic Fibrosis on children, young people, adults and their families. Open. Non-commercial
VX15-371-101: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi (Vertex Pharmaceuticals). Completed. Commercial
LCI –SEARCH: Lung Clearance Index (LCI) as a Sensitive measure of Early Airway Change in Cystic Fibrosis (Use of lung clearance index to improve detection of changes in lung function in cystic fibrosis). Non-commercial. Completed
Caregiver Burden in Cystic Fibrosis: Exploring the caregiver burden of Cystic Fibrosis in the United States, Germany, United Kingdom, and Ireland (Vertex Pharmaceuticals). Completed. Commercial
